Marketing deal set for low-vision products

Concord, CA-Eschenbach Optik of America Inc. will work with Pulse Data HumanWare (PDH) to form what the companies are calling the largest low-vision product strategic marketing alliance in the Americas.

Related Videos
Related Content

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Unity Biotechnology announces results from Part A of the Phase 2 ENVISION study of UBX1325

March 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Unity Biotechnology announces results from Part A of the Phase 2 ENVISION study of UBX1325

March 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Unity Biotechnology announces results from Part A of the Phase 2 ENVISION study of UBX1325

March 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023
© 2023 MJH Life Sciences

All rights reserved.